Demetrios Braddock, MD, PhD, is among 10 physician-scientists named as recipients of the Harrington Discovery Institute 2024 Scholar-Innovator Award. The award provides a two-year drug-development grant for $100,000 to support breakthrough new treatments in a variety of diseases. Dr. Braddock’s award will support his research in DNA-Degrading Enzyme for the Treatment of Lupus.
Award recipients also receive guidance and oversight in drug and business development, including regulatory assistance, the opportunity to compete for acceleration funds up to $300,000, and to qualify for mission-related investment funds typically up to $2M.
Harrington Discovery Institute at University Hospitals in Cleveland is an international drug discovery and development organization established to address unmet therapeutic needs. The Institute provides comprehensive support to leading scholars and entrepreneurs across academic centers in the US, UK, and Canada with a focus on medical breakthroughs that show great promise but otherwise would not advance to clinical trials.
Chen Liu, MD, PhD, Anthony N. Brady Professor of Pathology and Chair of Yale Pathology, praised Dr. Braddock.
“Congratulations to Dr. Braddock on winning this prestigious award,” Dr. Liu said. “This award is a testament not only to the excellent work Dr. Braddock does as well as the work being done in the Braddock Lab, but it also reflects positively on all the physician-scientists at Yale Pathology.”
This is the 12th class of Scholar-Innovators, according to Jonathan S. Stamler, MD, President, Harrington Discovery Institute, Distinguished University Professor and Robert S. and Sylvia K. Reitman Family Foundation Professor of Cardiovascular Innovation at University Hospitals and Case Western Reserve University. He said Harrington Scholar-Innovators “are accomplished physician-scientists whose research demonstrates innovation, creativity and the potential for clinical impact.”
Dr. Braddock is an Associate Professor of Pathology and Principal Investigator of the Braddock Lab, which studies diseases associated with enzyme deficiencies, focusing on severe unmet medical illness in the pediatric population.